

Breast Cancer Pathways: Endocrine Therapy for Advanced/Metastatic Disease

Patient Name: _____

Date of Birth: _____

Member Number: _____

Treatment Start Date: _____

Pathology: _____

Stage: _____

Line of Therapy: __1st Line __2nd Line __3rd Line __3rd Line+

ECOG Performance Status: _____ **ICD-10 Code:** _____

Biomarkers/Characteristics: (select all that apply)

Estrogen Receptor (ER): __Negative __Positive

Menopausal Status: __Pre __Peri

Progesterone Receptor (PR): __Negative __Positive

__Post __N/A (patient is male)

HER2 status by FISH/CISH: __Negative __Positive __Equivocal

Include ovarian suppression (pre-menopause only):

or by IHC: __0 __1+ __2+ __3+

__Yes __No __Unknown

Advanced/Metastatic Disease | Hormone Receptor Positive | First Line of Therapy (1st Line)

- Anastrozole (Arimidex)*
- Anastrozole (Arimidex) and palbociclib (Ibrance)*
- Anastrozole (Arimidex) and ribociclib (Kisqali)*
- Fulvestrant (Faslodex)* high dose
- Fulvestrant (Faslodex) and ribociclib (Kisqali)*
- Letrozole (Femara)*
- Letrozole (Femara) and palbociclib (Ibrance)*
- Letrozole (Femara) and ribociclib (Kisqali)*
- Tamoxifen†

Advanced/Metastatic Disease | Hormone Receptor Positive | Second and Subsequent Lines of Therapy (2nd Line+)

- Anastrozole (Arimidex)*
- Exemestane (Aromasin)*
- Fulvestrant (Faslodex) high dose*
- Fulvestrant (Faslodex) and palbociclib (Ibrance)**
- Fulvestrant (Faslodex) and ribociclib (Kisqali)**
- Letrozole (Femara)*
- Tamoxifen†

Advanced/Metastatic Disease | Hormone Receptor Positive | HER2 Positive | First and Subsequent Lines of Therapy (1st Line+)

- Anastrozole (Arimidex) and trastuzumab*
- Letrozole (Femara) and trastuzumab*

Advanced/Metastatic Disease | Hormone Receptor Positive | HER2 Negative | PIK3CA Mutated | Second and Subsequent Line (2nd Line+)

- Fulvestrant (Faslodex) and alpelisib (PIQRAY)*§

* With ovarian suppression for premenopausal individuals. Ovarian suppression utilizes LHRH agonists given as monthly injections. 3-month depot dosing does not reliably suppress estrogen levels.

† Tamoxifen is considered pathway for premenopausal individuals with or without ovarian suppression

‡ Palbociclib and ribociclib regimens are not considered pathway when continued in the second line setting if the patient has received an available CDK4/6 inhibitor regimen in the first line setting

§ After progression on prior therapy with a CDK 4/6 inhibitor

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.



8600 West Bryn Mawr Avenue
South Tower - Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Last review: 2/25/2020 | Effective date: 5/4/2020

Appropriate.Safe.Affordable

© 2020 AIM Specialty Health
9002-0720